Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic

Remdesivir (GS-5734), a drug initially developed to treat hepatitis C and Ebola virus disease, was the first approved treatment for severe coronavirus disease 2019 (COVID-19). However, apart from remdesivir, there is a paucity of other specific anti-viral agents against SARS-CoV-2 infection. In 2017...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Metabol Open
Main Authors: Vallianou, Natalia G., Tsilingiris, Dimitrios, Christodoulatos, Gerasimos Socrates, Karampela, Ιrene, Dalamaga, Maria
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2021
Assuntos:
Articles from the Vaccines, Immune Response, Therapeutic interventions and COVID-19 Special Issue
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8143911/
https://ncbi.nlm.nih.gov/pubmed/34056571
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.metop.2021.100096
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares